Department of Medicine/Division of Rheumatology, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
J Invest Dermatol. 2018 Apr;138(4):760-767. doi: 10.1016/j.jid.2017.10.024. Epub 2017 Nov 2.
Relatively little is known about the risk for incident liver disease in psoriasis (PsO), psoriatic arthritis (PsA), and rheumatoid arthritis (RA). We performed a cohort study among patients with PsO, PsA, or RA and matched controls in The Health Improvement Network from 1994 to 2014. Outcomes of interest were any liver disease, nonalcoholic fatty liver disease, and cirrhosis (any etiology). Among patients with PsO (N = 197,130), PsA (N = 12,308), RA (N = 54,251), and matched controls (N = 1,279,754), the adjusted hazard ratios for any liver disease were elevated among patients with PsO (without systemic therapy [ST] 1.37; with ST 1.97), PsA (without ST 1.38; with ST 1.67), and RA without an ST (1.49) but not elevated in patients with RA prescribed an ST (0.96). Incident nonalcoholic fatty liver disease was highest in patients with PsO prescribed an ST (2.23) and PsA with an ST (2.11). The risk of cirrhosis was highest among patients with PsO with an ST (2.62) and PsA without an ST (3.15). Additionally, the prevalence of liver disease and cirrhosis increased in a stepwise fashion with increasing body surface area affected by PsO (P for trend <0.001). More so than RA, PsO and PsA are associated with liver disease, particularly nonalcoholic fatty liver disease and cirrhosis, and this was true even among patients without ST exposure.
人们对银屑病(PsO)、银屑病关节炎(PsA)和类风湿关节炎(RA)患者发生肝脏疾病的风险知之甚少。我们在 1994 年至 2014 年间,在健康改善网络(Health Improvement Network)中进行了一项队列研究,纳入了患有 PsO、PsA 或 RA 的患者以及匹配对照。主要研究结局为任何肝脏疾病、非酒精性脂肪性肝病和肝硬化(任何病因)。在患有 PsO(N=197130)、PsA(N=12308)、RA(N=54251)和匹配对照(N=1279754)的患者中,患有 PsO(无系统治疗[ST] 1.37;有 ST 1.97)、PsA(无 ST 1.38;有 ST 1.67)和未接受 ST 的 RA(1.49)患者的任何肝脏疾病发生风险比升高,但接受 ST 的 RA 患者(0.96)未升高。未接受 ST 的 PsO 患者(2.23)和 PsA 患者(2.11)发生非酒精性脂肪性肝病的风险最高。接受 ST 的 PsO 患者(2.62)和无 ST 的 PsA 患者(3.15)的肝硬化风险最高。此外,随着银屑病受累体表面积的增加,肝脏疾病和肝硬化的患病率呈阶梯式上升(趋势 P 值<0.001)。与 RA 相比,PsO 和 PsA 与肝脏疾病,特别是非酒精性脂肪性肝病和肝硬化相关,即使在未暴露于 ST 的患者中也是如此。